Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis

Gastroenterology

Volumn 149, Issue 2, 2015, Pages 350-355.e2

  Brandse, Johannan F ^a,b   Van Den Brink, Gijs R ^a,b   Wildenberg, Manon E ^b   Van Der Kleij, Desiree ^c   Rispens, Theo ^d   Jansen, Jeroen M ^e   Mathôt, Ron A ^b   Ponsioen, Cyriel Y ^a   Löwenberg, Mark ^a   D'Haens, Geert R A M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

^d SANQUIN RESEARCH   (Netherlands)

^e ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

IBD; Inflammatory Bowel Disease; Intestinal Loss of Protein; Monoclonal Antibody Therapy

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; HEMOGLOBIN; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; COLITIS, ULCERATIVE; DRUG EFFECTS; DRUG MONITORING; FECES; INTESTINE MUCOSA; MIDDLE AGED; NETHERLANDS; PATHOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG MONITORING; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; HUMANS; INFLIXIMAB; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NETHERLANDS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938090411     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.04.016     Document Type: Article

References (32)

1. S.B. Hanauer, B.G. Feagan, G.R. Lichtenstein, and et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 2002 1541 1549
2. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, and et al. Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2005 2462 2476
3. H. Yanai, and S.B. Hanauer Assessing response and loss of response to biological therapies in IBD Am J Gastroenterol 106 2011 685 698
4. F. Baert, M. Noman, S. Vermeire, and et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 2003 601 608
5. E.A. Maser, R. Villela, M.S. Silverberg, and et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Clin Gastroenterol Hepatol 4 2006 1248 1254
6. C.H. Seow, A. Newman, S.P. Irwin, and et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis Gut 59 2010 49 54
7. E.O. Glocker, D. Kotlarz, K. Boztug, and et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor N Engl J Med 361 2009 2033 2045
8. R. Atreya, M. Zimmer, B. Bartsch, and et al. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages Gastroenterology 141 2011 2026 2038
9. A.C. Vos, M.E. Wildenberg, M. Duijvestein, and et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner Gastroenterology 140 2011 221 230
10. A.C. Vos, M.E. Wildenberg, I. Arijs, and et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro Inflamm Bowel Dis 18 2012 401 408
11. R. Atreya, H. Neumann, C. Neufert, and et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease Nat Med 20 2014 313 318
12. I. Ordas, D.R. Mould, B.G. Feagan, and et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin Pharmacol Ther 91 2012 635 646
13. U. Klotz, A. Teml, and M. Schwab Clinical pharmacokinetics and use of infliximab Clin Pharmacokinet 46 2007 645 660
14. A.A. Fasanmade, O.J. Adedokun, A. Olson, and et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis Int J Clin Pharmacol Ther 48 2010 297 308
15. D.R. Mould, and K.R. Sweeney The pharmacokinetics and pharmacodynamics of monoclonal antibodies - mechanistic modeling applied to drug development Curr Opin Drug Discov Devel 10 2007 84 96
16. M.A. Tabrizi, C.M. Tseng, and L.K. Roskos Elimination mechanisms of therapeutic monoclonal antibodies Drug Discov Today 11 2006 81 88
17. D.R. Mould, and B. Green Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development BioDrugs 24 2010 23 39
18. N. Kapel, D. Meillet, L. Favennec, and et al. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn's disease and ulcerative colitis Eur J Clin Chem Clin Biochem 30 1992 197 202
19. D. Kevans, S. Murthy, A. Iacono, and et al. Sa2031 Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure Gastroenterology 142 Suppl 1 2012 S384 S385
20. R.S. Walmsley, R.C. Ayres, R.E. Pounder, and et al. A simple clinical colitis activity index Gut 43 1998 29 32
21. N. Vande Casteele, D.J. Buurman, M.G. Sturkenboom, and et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays Aliment Pharmacol Ther 36 2012 765 771
22. G.J. Wolbink, M. Vis, W. Lems, and et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis Arthritis Rheum 54 2006 711 715
23. T. Rispens, H. de Vrieze, E. de Groot, and et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing J Immunol Methods 375 2012 93 99
24. S.L. Jowett, C.J. Seal, E. Phillips, and et al. Defining relapse of ulcerative colitis using a symptom-based activity index Scand J Gastroenterol 38 2003 164 171
25. K.W. Schroeder, W.J. Tremaine, and D.M. Ilstrup Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study N Engl J Med 317 1987 1625 1629
26. G. D'Haens, W.J. Sandborn, B.G. Feagan, and et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis Gastroenterology 132 2007 763 786
27. N. Steck, K. Mueller, M. Schemann, and et al. Bacterial proteases in IBD and IBS Gut 61 2012 1610 1618
28. G. Jarnerot, E. Hertervig, I. Friis-Liby, and et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study Gastroenterology 128 2005 1805 1811
29. D. Laharie, A. Bourreille, J. Branche, and et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial Lancet 380 2012 1909 1915
30. A. Oussalah, L. Evesque, D. Laharie, and et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization Am J Gastroenterol 105 2010 2617 2625
31. A.J. Yarur, S. Hauenstein, D. Sussman, and et al. Correlation of intestinal tissue anti-TNF drug levels with endoscopic disease activity in patients with inflammatory bowel disease: the ATLAS study Gut 2015 Feb 10
32. D.J. Gibson, Z.S. Heetun, C.E. Redmond, and et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis Clin Gastroenterol Hepatol 13 2015 330 335.e1